Provided are a recombinant poliovirus-like particle immune composition, a preparation method therefor, and use thereof. The recombinant poliovirus-like particle immune composition comprises type I, type II, and/or type III poliovirus-like particles, wherein the type I, type II, and/or type III poliovirus-like particles have a suitable particle content. The prepared recombinant poliovirus-like particle immune composition and vaccine have a simple constituent and a weak side effect, and have significant advantages in the aspects of safety, immune efficacy, stability, and adaptability relative to existing inactivated vaccines and attenuated vaccines.
A61K 39/295 - Antigènes viraux polyvalentsMélanges d'antigènes viraux et bactériens
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61P 31/14 - Antiviraux pour le traitement des virus ARN
2.
MULTIVALENT STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE COMPOSITION, PREPARATION METHOD THEREFOR, AND USE THEREOF
Disclosed are a multivalent Streptococcus pneumoniae capsular polysaccharide-protein conjugate composition and a preparation method therefor. The Streptococcus pneumoniae serotype is selected from 1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F. The composition can effectively stimulate the production of helper T cells in the body, promote the activation of B cells, and result in immune memory, so as to enable the antibody class to switch from IgM to IgG and enhance immunogenicity, thereby enabling the infants under 2 years of age to produce effective immune responses against corresponding diseases.
Provided is an immunogenic composition. The immunogenic composition comprises at least two antigens, providing a specific combination of Neisseria meningitidis antigens, said combination being capable of enabling the immunogenic composition to have significantly improved efficacy against Neisseria meningitidis infection. The synergistic combination of the specific antigen combination achieves responses higher than the sum of responses initiated by the antigens alone. Aiming at Chinese epidemiological research, the immunogenic composition for wider coverage of MenB strains is developed.
Provided is an immunogenic composition comprising at least two antigens. Provided is a specific combination of Neisseria meningitidis antigens, which can significantly improve the efficacy of the immunogenic composition against Neisseria infection. The synergistic combination of the specific antigen combination is greater than the additive reaction triggered by the antigens alone. On the basis of epidemiological studies in China, the immunogenic composition targeting a broader coverage of MenB strains is developed.
Disclosed are a nebulization cup and application in nebulized inhalation administration thereof, and especially application in nebulized inhalation administration of a preventive and/or therapeutic drug for a respiratory disease (such as SARS-CoV-2 vaccine). After adding an antistatic agent, the nebulization cup can effectively maintain the stability of drug mist within a certain period of time, with stable particle size, less drug residue in the cup, thus ensuring effective inhalable amount, and the administration operation is simple and convenient, thus the nebulization cup can significantly improve the inoculation efficiency and can be used for large-scale inoculation.
A method for characterizing inhalation vaccine performance. The method comprises quantitatively linking an NGI cascade impactor, quantitative real-time polymerase chain reaction (QPCR), and droplet digital PCR (ddPCR) to establish a complete performance characterization method for inhalation vaccines. A testing environment with stable results and high repeatability has been obtained by in-depth analysis of the various influencing factors that the NGI cascade impactor has in respect of inhalation vaccine characterization. Meanwhile, the optimal characterization sample dosage has been determined on the basis of multiple repeated experiments. The present application innovatively proposes combining NGI, QPCR and ddPCR; the method allows for accurate testing that takes little time, and testing of large batch samples can be accomplished, ensuring scalable application in industry.
The present invention relates to a vaccine formulation. An effective ingredient is a recombinant chimpanzee adenovirus expressing an antigen protein, and adjuvants are ethanol and glycerol. The present formulation has no animal-derived ingredient and has high safety. The formulation can maintain good stability of a chimpanzee adenoviral vector vaccine liquid formulation. The vaccine formulation can be stably stored for more than 12 months at 2-8°C, the abnormal toxicity test of the vaccine formulation satisfies the standards, and the vaccine formulation is safe to use. The vaccine formulation can be used as a liquid injection and an atomized inhalation formulation at the same time.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD. (Chine)
Inventeur(s)
Ge, Chen
Zhu, Tao
Qiu, Dongxu
Liu, Jian
Wang, Haomeng
He, Jun
Yan, Zhihong
Wang, Zhenghua
Abrégé
The present disclosure relates to a nucleic acid-lipid nanoparticle composition and a lyophilized preparation thereof, and further relates to a preparation method for the composition and a use of the composition. The nucleic acid-lipid nanoparticle composition of the present disclosure comprises lactate, so that the stability of nucleic acid-lipid nanoparticles is improved in a lyophilization process and a prepared lyophilized preparation. According to the present disclosure, the total time of a freeze-drying process for the nucleic acid-lipid nanoparticles can be shortened, and energy consumption and the time cost of product scale-up production can be greatly reduced; the rehydration of lyophilized nucleic acid-lipid nanoparticles is quick, and the total amount of nucleic acids, the encapsulation efficiency, and the nucleic acid integrity are high; in addition, a lyophilized and rehydrated preparation has cell transfection efficiency not significantly different from that of a non-lyophilized nucleic acid-lipid nanoparticle stock solution, and has a high in vivo immune response, even exceeding that of the non-lyophilized nucleic acid-lipid nanoparticle stock solution.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
9.
ADENOVIRAL VECTOR VACCINE, AND PREPARATION METHOD AND USE THEREOF
Provided are a modified recombinant adenoviral vector, and a preparation method and use thereof. The modified adenoviral vector can reduce the negative charge level on the surface of adenovirus particles, so as to reduce interaction between the adenoviral vector and PF4 (platelet factor 4). By administering the modified adenovirus vector, the risk of thrombus can be reduced, vaccine safety and effectiveness are improved, and the vaccine is more suitable for high-risk crowds such as elder people, children and pregnant women. The recombinant adenovirus can be widely used for gene therapy, tumor immunization and/or antiviral vaccination, including the use of initiating a primary immune response in a human or mammal to initiate a reinforced immune response for destroying the tolerance of a host to an autoantigen. The modified recombinant adenovirus can be used for developing a mucosal administration formulation. Compared with injection, the mucosal administration formulation has compliance and also lower dosage, and can generate triple protection effects of humoral immunity, cellular immunity and mucosal immunity.
Provided is a combined vaccine, which can respectively reduce the number of instances of vaccination for infants, adults and teenagers, and reduce the cost of vaccination. The combined vaccine comprises: a) a conjugate of a Haemophilus influenzae type b (Hib) antigen and a carrier protein; b) a conjugate of a meningococcal polysaccharide and a protein, which conjugate contains a conjugate of group A epidemic meningococcal capsular polysaccharide and a carrier protein, a conjugate of group C epidemic meningococcal capsular polysaccharide and a carrier protein, a conjugate of group Y epidemic meningococcal capsular polysaccharide and a carrier protein, and a conjugate of group W135 epidemic meningococcal capsular polysaccharide and a carrier protein; c) a diphtheria-tetanus-pertussis (three-component pertussis or five-component pertussis) vaccine, etc. The carrier proteins involved in the combined vaccine are specifically screened. Experimental results show that the combined vaccine prepared from the specifically selected carrier proteins can induce the body to generate good immune responses and improve the immunization coverage.
The present invention relates to an inhaled aerosol vaccine, and in particular to a recombinant adenovirus vector inhaled aerosol vaccine, a preparation method therefor and a use thereof. The inhaled aerosol vaccine can simultaneously express one or more antigens. After inhaling and mucosal immunization are carried out on the body, a high-level specific antibody can be generated in the lung and the body at the same time, and a high cell immune response can be generated by means of stimulation. In addition, the vaccine is an inhaled preparation, which can effectively stimulate mucosal immunization and increase the third protection of the body. The recombinant adenovirus vector vaccine has good stability, is safe, efficient and painless, and can effectively cope with the recurrence of emerging infections and latent infections of bacteria and viruses.
Provided is an immunogenic composition, the immunogenic composition comprising one or more pulmonary tuberculosis antigens. After performing mucosal immunization on the body via inhalation, the invention not only has a high level of specific antibodies targeting mycobacterium tuberculosis simultaneously generated in the lungs and body, but can also stimulate a very high cell immune response.
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
C12N 7/00 - Virus, p. ex. bactériophagesCompositions les contenantLeur préparation ou purification
Provided is a purification process capable of linearly amplifying virus-like particles. A recombinantly expressed virus-like particle protein is purified by means of technical routes, and the purity of the prepared virus-like particle protein is at least higher than 90%. Moreover, the host protein residue, the host nucleic acid residue, and the virus residual quantity are all lower than the relevant content requirements in the pharmacopeia, and the commercial production scale of 2000 L of a fermentation liquor is supported.
The present invention provides a pertussis toxin (PT) detoxification method, a detoxified PT antigen prepared by the method, and a diphtheria, tetanus and acellular pertussis combined vaccine. Formaldehyde and glutaraldehyde are used as detoxification agents for a PT antigen, and the detoxification sequence is as follows: formaldehyde is used for treatment and detoxification first, and then glutaraldehyde is used for detoxification. The diphtheria, tetanus and acellular pertussis combined vaccine adsorbed prepared after detoxification has good immunogenicity and titer, and is low in toxicity, safe, effective and controllable in quality.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
Provided in the present invention are a recombinant poliovirus-like particle vaccine preparation, a preparation method therefor and the use thereof. The vaccine comprises recombinant virus-like particle antigens of three serotypes, and comprises an adjuvant. Preferably, the adjuvant is an aluminum adjuvant. Preferably, the adjuvant is aluminum phosphate (AP), aluminum hydroxide treated with different concentrations of phosphates (PTAH), and aluminum hydroxide.
Provided are a vector for expressing poliovirus-like particles, a preparation method therefor, and use thereof. The vector comprises genes encoding VP0, VP1 and VP3 proteins, wherein any two of the VP0, VP1 and VP3 genes are linked by means of an Intein-self-cleavage sequence and are inserted downstream of a promoter of a first expression cassette, and the remaining gene is inserted downstream of a promoter of a second expression cassette, thus obtaining a recombinant plasmid comprising the gens for the structural proteins of the poliovirus-like particles. The described vector, due to the lack of 3CD genotoxicity, has good stability and significantly improved yield. The vector, due to the absence of a residual linker sequence, is close to the native conformation. The poliovirus type I, type II and type III-like particles prepared using the technical route can be used for preparing a virus-like particle-based poliovirus vaccine that can elicit higher levels of neutralizing antibodies against poliovirus infection.
Provided are a recombinant poliovirus-like particle (PVLP), a preparation method therefor, and a use. The mutation design of the recombinant poliovirus-like particle is based on a structural protein mutation combination, which not only enhances the thermal stability of the PVLP, but also improves the immunogenicity of the PVLP.
C12N 15/00 - Techniques de mutation ou génie génétiqueADN ou ARN concernant le génie génétique, vecteurs, p. ex. plasmides, ou leur isolement, leur préparation ou leur purificationUtilisation d'hôtes pour ceux-ci
Disclosed herein are an atomization inhalation bag and use thereof in atomization inhalation administration, and in particular, use in atomization inhalation administration of a drug for the prevention and/or treatment of a respiratory system disease. The atomization inhalation bag can effectively maintain the stability of a drug aerosol within a certain period of time, with a stable particle size state, and fewer drug left in the bag, such that an effective inhalation amount of the drug is ensured, and an administration operation is simple and convenient, such that the inoculation efficiency is significantly improved, and thus the atomization inhalation bag can be used for large-scale inoculation.
Provided are a vaccine auxiliary material and use thereof. A formulation comprises an effective component and an auxiliary material. The effective component is a recombinant chimpanzee adenovirus expressing an antigen protein. The auxiliary material comprises a protective agent. The protective agent comprises one or more of ethanol, glycerol or propylene glycol. Preferably, the protective agent comprises ethanol and glycerol. Preferably, the protective agent comprises propylene glycol and glycerol. The formulation has no animal-derived components and is high in safety. The formulation can keep good stability of the chimpanzee adenovirus vector–based liquid vaccine formulation. The formulation can be stably stored for more than 12 months at the temperature of 2-8 °C, and the abnormal toxicity test thereof is qualified, so that use is safe.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
An atomization-inhalation-type atomization drug administration device, comprising a drug administration control component, a drug storage component, an atomization component and a power supply component. The drug storage component is arranged in an upper housing (9) and is used to provide a medicinal liquid to the atomization component. The atomization component is arranged between the upper housing (9) and a lower housing (2), and is used to atomize the medicinal liquid provided by the drug storage component. The drug administration control component is used to control the operation of the atomization component. The power supply component is used to supply power to the drug administration control component and the atomization component. An atomization outlet is provided on the lower housing (2), and is used for discharging the atomized medicinal liquid. The atomization drug administration device can store and atomize a liquid drug preparation, and provide a patient with real-time atomization and inhalation to achieve effects such as treatment, immunization, or the like.
Provided in the present invention are a composition that fights respiratory syncytial virus (RSV) infection, a preparation method therefor, and a use thereof. The composition comprises a recombinant adenoviral vector, a gene encoding an RSV antigen is inserted into the recombinant adenoviral vector, and the composition is a mucosal administration preparation.
CANSINO (SHANGHAI) BIOLOGICAL RESEARCH CO., LTD. (Chine)
Inventeur(s)
Wang, Haomeng
Li, Mingyuan
Yan, Zhihong
Jia, Lin
Liu, Jian
Ma, Wenlin
Qiu, Dongxu
Xie, Yanbo
Yu, Xuefeng
Yu, Peng
Zhu, Tao
Abrégé
Based on the physicochemical principles of the freeze-drying process, the present invention performs systematic research on the freeze-drying conditions of nucleic acid-lipid nanoparticles, namely a freeze-drying process and a freeze-drying protective agent, optimizing and designing an efficient freeze-drying method suitable for the nucleic acid-lipid nanoparticles. According to the invention, the total duration of the nucleic acid-lipid nanoparticle freeze-drying process can be reduced to 8-18 hours, significantly reducing the energy consumption and the time cost of scaled-up product production; the freeze-dried nucleic acid-lipid nanoparticles rehydrate rapidly (within 10 seconds), and have a high total nucleic acid content, entrapment efficiency and nucleic acid integrity; moreover, the cell transfection efficiency of a freeze-dried rehydrated preparation is not significantly different from that of a nucleic acid-lipid nanoparticle stock solution which has not been freeze-dried, and the in-vivo immune response is high and even exceeds that of a nucleic acid-lipid nanoparticle stock solution which has not been freeze-dried.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A61P 31/16 - Antiviraux pour le traitement des virus ARN de la grippe ou des rhinovirus
A61P 31/20 - Antiviraux pour le traitement des virus ADN
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
A61J 3/02 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration la forme de poudres
23.
MRNA SARS-COV-2 VACCINE, METHOD FOR PREPARING SAME, AND USE THEREOF
Disclosed are an mRNA SARS-CoV-2 vaccine, a method for preparing same, and use thereof. The mRNA SARS-CoV-2 vaccine can induce strong specific humoral and/or T cell immune response against SARS-CoV-2, and can induce the production of a neutralizing antibody capable of neutralizing various viral variants. The delivery vector of the mRNA SARS-CoV-2 vaccine has good stability, high delivery efficiency, safety, efficacy, and controlled quality.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 47/28 - Stéroïdes, p. ex. cholestérol, acides biliaires ou acide glycyrrhétinique
A61P 31/14 - Antiviraux pour le traitement des virus ARN
C12N 15/50 - Coronaviridae, p. ex. virus de la bronchite infectieuse, virus de la gastro-entérite transmissible
C07K 14/165 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
24.
METHOD FOR PREPARING ADENOVIRUS VECTOR VACCINE BY MEANS OF PERFUSION CULTURE PROCESS
Provided is a method for preparing an adenovirus vector vaccine by means of a perfusion culture process. The method comprises a step of culturing adenovirus host cells, and in particular a step of adjusting the perfusion rate by means of at least two stages according to cell density. The method increases the single cell yield of a virus after infection and the specific activity of a virus harvest liquid while achieving high-density growth of adenovirus host cells.
An atomization drug delivery device, which has a high degree of automation, is capable of accurately performing drug delivery and can be used for large-scale vaccine inoculation, comprising a power unit (2), a transmission module (3), a drug storage unit (4), and an atomization module (6), the power unit (2) being connected to the transmission module (3), and the drug storage unit (4) being connected to the atomization module (6). The drug storage unit (4) comprises a push rod (4-1) and a drug storage cylinder (4-2), the push rod (4-1) being connected to the drug storage cylinder (4-2) in a sliding sealing manner. The power unit (2), by means of the transmission module (3), actuates the push rod (4-1). The push rod (4-1) discharges a drug liquid in the drug storage cylinder (4-2) and conveys same to the atomization module (6), and the atomization module (6) atomizes the drug liquid.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Pharmaceutical preparations, namely, antivirals; Chemical preparations for pharmaceutical purposes, namely, for the treatment of infectious diseases; Vaccines; Medicines for the treatment of infectious diseases; Cultures of microorganisms for medical or veterinary use; Chemical preparations for medical purposes, namely, for the treatment of infectious diseases; Injectable pharmaceuticals for treatment of anaphylactic reactions; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; biochemical medicines for the treatment of infectious diseases, namely, biochemical reagents for medical purposes; Bacteriological culture mediums
27.
PEN-SHAPED DRUG DELIVERY DEVICE FOR INHALATION OF NEBULIZED DRUGS
Provided is a pen-shaped drug delivery device for inhalation of nebulized drugs, comprising a quantitative drug delivery control device, a drug cartridge securing device (20), and a nebulization device (17). The pen-shaped nebulizer can be used to generate drug mists for inhalation by a subject, thus achieving therapeutic, immunological or other effects. Vaccines are directly filled into cartridges, which are used in combination with a liquid dispensing pen, thus eliminating the solution extraction procedure, reducing the workload of vaccinators, and avoiding the risk of injuries due to drug extraction in the use of syringes puncturing rubber stoppers. The liquid dispensing needle punctures the disposable cartridge, thus minimizing fragments due to multiple drug extractions in the use of syringes. By means of precise dispensing, the pen-shaped nebulizer can reduce the waste of drug solutions and facilitates transportation.
The present invention provides a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. It is found that the lipid nanoparticle mRNA vaccine prepared in the present invention by selecting a specific cationic lipid has better in-vitro stability and immunogenicity than LNPs prepared from cationic lipids in the prior art.
C07C 219/06 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé les groupes hydroxy étant estérifiés par des acides carboxyliques ayant les groupes carboxyle estérifiants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
C07C 255/24 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au même squelette carboné acyclique saturé
C07C 229/12 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons à des atomes de carbone de squelettes carbonés acycliques
C07C 233/36 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 215/14 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique l'atome d'azote du groupe amino étant de plus lié à des groupes hydrocarbonés substitués par des groupes amino
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
The present invention provides a novel cationic lipid, a lipid nanoparticle, and a nucleic acid vaccine. According to the present invention, a specific cationic lipid is selected to prepare a lipid nanoparticle mRNA vaccine, and the lipid nanoparticle mRNA vaccine is found to have better in-vitro stability and immunogenicity as compared with the prior art.
C07C 217/08 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe hydroxy éthérifié et un seul groupe amino liés au squelette carboné, qui n'est pas substitué par ailleurs l'atome d'oxygène du groupe hydroxy éthérifié étant lié de plus à un atome de carbone acyclique
C07C 219/06 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé les groupes hydroxy étant estérifiés par des acides carboxyliques ayant les groupes carboxyle estérifiants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
C07C 255/24 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au même squelette carboné acyclique saturé
C07C 233/36 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 215/14 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique l'atome d'azote du groupe amino étant de plus lié à des groupes hydrocarbonés substitués par des groupes amino
A61K 39/145 - Orthomyxoviridae, p. ex. virus de l'influenza
Provided in the present invention are a novel cationic lipid, a lipid nanoparticle and a nucleic acid vaccine. In the present invention, a specific cationic lipid is selected for preparing a lipid nanoparticle mRNA vaccine, which is found to have better in-vitro stability and can stimulate a stronger immunoreaction compared with LNPs prepared from cationic lipids in the prior art.
C07C 219/06 - Composés contenant des groupes amino et hydroxy estérifiés liés au même squelette carboné ayant des groupes hydroxy estérifiés et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé les groupes hydroxy étant estérifiés par des acides carboxyliques ayant les groupes carboxyle estérifiants liés à des atomes d'hydrogène ou à des atomes de carbone acycliques d'un squelette carboné acyclique saturé
C07C 255/24 - Nitriles d'acides carboxyliques ayant des groupes cyano liés à des atomes de carbone acycliques contenant des groupes cyano et des atomes d'azote, liés par des liaisons simples et n'étant pas liés de plus à d'autres hétéro-atomes, liés au même squelette carboné acyclique saturé
C07C 229/12 - Composés contenant des groupes amino et carboxyle liés au même squelette carboné ayant des groupes amino et carboxyle liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant acyclique et saturé ayant un seul groupe amino et un seul groupe carboxyle liés au squelette carboné l'atome d'azote du groupe amino étant lié de plus à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons à des atomes de carbone de squelettes carbonés acycliques
C07C 233/36 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des groupes amino avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 215/14 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy et des groupes amino liés à des atomes de carbone acycliques du même squelette carboné le squelette carboné étant saturé et acyclique l'atome d'azote du groupe amino étant de plus lié à des groupes hydrocarbonés substitués par des groupes amino
A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
Disclosed is an inhalation administration delivery system of a recombinant adenovirus vector vaccine. In the delivery system, an adenovirus vector is reformed and matched with a specific preparation prescription, and after being administered by means of inhalation, the vaccine can reach the lungs by means of nasal inhalation or mouth inhalation, so that a protective immune response including mucosal immunity is generated, the effective utilization rate of the vaccine is increased, the pre-existing immunity of an adenovirus is solved, and an effect of the vaccine is improved.
Provided are a protein antigen subjected to site-directed mutation and site-directed modification, and a method for site-directed mutation and site-directed modification of the protein antigen. The method comprises: site-directedly introducing an unnatural amino acid into a specific site of the protein antigen by genetic codon expansion technique; and performing site-directed modification with the protein antigen by the unnatural amino acid and a modifier, wherein the modifier is a receptor agonist such as tripalmitoyl-S-glyceryl cysteine and monophosphoryl lipid A. Further provided is use of the protein antigen subjected to site-directed mutation and site-directed modification, such as use as a vaccine.
C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
Disclosed is a SARS-CoV-2 vaccine, wherein the S protein of SARS-CoV-2 serves as the antigen, and the vaccine comprises an adenoviral vector, and the vaccine induces an improved protective immune response through mucosal immunity, thus preventing SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.
A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
A61K 47/42 - ProtéinesPolypeptidesLeurs produits de dégradationLeurs dérivés p. ex. albumine, gélatine ou zéine
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61P 31/14 - Antiviraux pour le traitement des virus ARN
A cup having an atomizing inhalation function, comprising a cup body (1) and a cup lid (2). The cup lid (2) is provided with an atomization port (21) and an inhalation nozzle (24). By means of the inhalation nozzle (24), a patient can inhale a medicinal liquid mist into the respiratory tract and the lungs through the mouth, so as to achieve a therapeutic effect. After atomization, the inhalation nozzle can be sealed by means of a plug (25) to prevent the remaining mist from escaping from the cup.
A nebulizer cup and a use thereof in nebulization inhalation administration, in particular, the use of the nebulizer cup in the nebulization inhalation administration of drugs (e.g. SARS-CoV-2 vaccine) for preventing and/or treating respiratory system diseases . After adding an anti-static agent into the nebulizer cup, the stability of the drug aerosol can be effectively maintained within a certain time, the particle size state is stable, the drug residues in the cup are few, an effective inhalable amount is ensured, the administration operation is simple and convenient, the inoculation efficiency can be obviously improved, and the nebulizer cup can be used for large-scale inoculation.
The present invention relates to a carrier protein with site-directed mutation and use thereof in preparation of a vaccine, wherein the carrier protein is selected from fusion proteins formed by one, two or more of diphtheria toxoid, a non-toxic mutant of diphtheria toxin, a bacterial outer membrane protein and a bacterially expressed protein, wherein an amino acid at at least one site on the carrier protein is mutated into an unnatural amino acid, and the unnatural amino acid contains an azido or alkynyl terminal group. In a mutual reaction process of the carrier protein with site-directed mutation of the present invention and a polysaccharide antigen, a covalent bond is formed, and meanwhile a formed conjugate is in a bead-string state, so that the carrier protein and the polysaccharide antigen can be effectively prevented from being excessively crosslinked. Further, particle size distribution of the conjugate is significantly uniform and controllable, which provides an effective means for improving quality of a polysaccharide-protein conjugate vaccine.
The present invention provides a glycoconjugate and an immunogenic composition comprising the glycoconjugate, and also provides a preparation method for the glycoconjugate, which comprises: oxidizing a primary hydroxyl group of bacterial capsular polysaccharide, which is conjugated to a carrier protein directly or by passing through a spacer group, so as to prepare and obtain a glycoconjugate. Also disclosed are an application of the glycoconjugate and immunogenic composition in the preparation of a drug or vaccine to prevent and/or treat individual Streptococcus pneumoniae infections and diseases related to Streptococcus pneumoniae.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A glycoconjugate, a specific method for preparing same by means of deriving a carboxyl group of a bacterial capsular polysaccharide from a spacer and then binding same to a carrier protein, and an immunogenic composition containing the glycoconjugate. Also disclosed is the use of the glycoconjugate and the immunogenic composition in the preparation of a drug or a vaccine for preventing and/or treating individual infections with Streptococcus pneumoniae and diseases related to same. The glycoconjugate has the characteristics of a higher immunogenicity and a higher bactericidal effect.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; pharmaceutical preparations;
vaccines; biological preparations for medical purposes;
dietetic foods adapted for medical purposes; depuratives;
medicinal health kit; sanitizing wipes; wadding for medical
purposes; disinfectants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; pharmaceutical preparations;
vaccines; biological preparations for medical purposes;
dietetic foods adapted for medical purposes; depuratives;
medicinal health kit; sanitizing wipes; wadding for medical
purposes; disinfectants.
41.
RECOMBINANT NOVEL CORONAVIRUS VACCINE USING REPLICATION-DEFICIENT HUMAN ADENOVIRUS AS VECTOR
Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; biological preparations for
medical purposes; pharmaceutical preparations; vaccines;
dietetic foods adapted for medical purposes; depuratives;
medical health care preparations; sanitizing wipes; wadding
for medical purposes; disinfectants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes; biological preparations for
medical purposes; pharmaceutical preparations; vaccines;
dietetic foods adapted for medical purposes; depuratives;
medical health care preparations; sanitizing wipes; wadding
for medical purposes; disinfectants.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Medicines for human purposes, namely, medicines for the treatment of diabetes, obesity, cancer, oncological diseases, cardiovascular and cerebrovascular diseases, influenza, respiratory diseases and asthma, gastrointestinal diseases, genitourinary diseases, neurological diseases, allergies, headaches, insomnia, bacteria-based diseases, ocular disorders or diseases; biological preparations for medical purposes for the treatment of cancer; pharmaceutical preparations, namely, anti-inflammatory preparations; analgesic preparations; anaesthetics and anti-infectives; vaccines; dietetic foods adapted for medical purposes; depuratives for the body; medical health care preparations, namely, health food supplements, dietary supplements for urinary health, vitamin preparations; sanitizing wipes; wadding for medical purposes; disinfectants
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Pharmaceutical preparations for use as anti-infectives; biological preparations made from living tissues for use in immunotherapy; antitumor drugs; vaccines for human use; dietetic foods adapted for medical purposes, namely, nutraceutical food and beverages for general health and well-being; depuratives, namely, air purifying preparations; in vitro diagnostic preparations for medical purposes; disposable sanitizing wipes; wadding for medical purposes; all purpose disinfectants.
Disclosed are a pharmaceutical composition and the use thereof, in particular a recombinant adenovirus vector vaccine composition, a vaccine preparation (in particular a liquid preparation) and the use thereof in preventing and/or treating diseases. The above-mentioned composition can be used to prepare a vaccine (in particular a recombinant vector vaccine, such as a recombinant adenovirus vector vaccine) preparation (in particular a liquid preparation). The vaccine preparation can effectively prevent antigen aggregation, has good stability, can be stored stably at 2-8°C for at least 2 years, at 25°C for at least 3 months, and at 37°C for at least 2 weeks, and can still maintain a relatively good antigenic activity after repeated freezing and thawing. In addition, an abnormal toxicity test performed thereon is qualified and same is safe to use.
A61K 47/22 - Composés hétérocycliques, p. ex. acide ascorbique, tocophérol ou pyrrolidones
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
Provided is a method for preparing an adenovirus vector vaccine by means of a perfusion culture process. The method comprises a step of culturing adenovirus host cells, and in particular a step of adjusting the perfusion rate by means of at least two stages according to cell density. The method increases the single cell yield of a virus after infection and the specific activity of a virus harvest liquid while achieving high-density growth of adenovirus host cells.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
Disclosed is an SamRNA vaccine, including a recombinant viral vector which includes: i) a viral gene replication complex including nucleotide sequences encoding viral gene replication-related proteins nsP1, nsP2, nsP3, and nsP4; and ii) a nucleotide sequence encoding at least one antigen. According to the SamRNA vaccine of the present invention, in addition to that a promoter of a modified adenoviral vector itself can transcribe an antigen gene to form mRNA, the viral gene replication-related proteins nsP1-4 use RNA as a template to synthesize a large amount of mRNAs, and the immune effect of a target antigen is greatly improved.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 31/22 - Antiviraux pour le traitement des virus ADN des virus de l'herpès
50.
CARRIER PROTEIN SUBJECTED TO SITE-DIRECTED MUTATION AND USE THEREOF IN PREPARATION OF VACCINE
Provided are a protein antigen subjected to site-directed mutation and site-directed modification, and a method for the site-directed mutation and site-directed modification of the protein antigen. The method comprises: introducing unnatural amino acids into specific sites of the protein antigen in a site-directed way by means of using a gene codon expansion technique; and performing site-directed modification with the protein antigen by means of using the unnatural amino acids and a modifier, wherein the modifier is a receptor agonist such as tripalmitoyl-S-glyceryl cysteine and monophosphoryl lipid A. Further provided is the use of the protein antigen subjected to site-directed mutation and site-directed modification, such as the use of same as a vaccine.
C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
C07K 1/10 - Procédés généraux de préparation de peptides utilisant des agents de couplage
Disclosed is a SARS-CoV-2 vaccine, for which the S protein of SARS-CoV-2 serves as the antigen, the form of the vaccine comprises an adenoviral vector vaccine, and the vaccine produces an improved protective immune response by means of transmucosal immunity, thus preventing a SARS-CoV-2 infection. Specifically, when atomized by an appropriate apparatus, the vaccine generates particles of improved uniformity, which can reach the lungs after being inhaled via the nasal cavity or the oral cavity, thus producing a protective immune response with respect to the entire respiratory tract and the lungs, enhancing the effective utilization rate of the vaccine, and increasing the effect of the vaccine.
Provided are an mRNA or an mRNA composition, and an mRNA vaccine comprising the mRNA or the mRNA composition. The mRNA or the mRNA composition comprises an mRNA sequence encoding an S protein of a novel coronavirus SARS-CoV-2 or a variant thereof, and an mRNA sequence encoding an RBD in the S protein or a variant thereof. Further provided are the applications of the mRNA or the mRNA composition, and the mRNA vaccine comprising the mRNA or the mRNA composition in preparation of a medication for preventing and/or treating a disease caused by a novel coronavirus SARS-CoV-2 infection.
Provided is a novel coronavirus vaccine using replication-deficient human type 5 adenovirus as a vector. The vaccine takes the replication-deficient human type 5 adenovirus that is lack of E1 and E3 in a combined mode as a vector, and HEK293 cells that integrate adenovirus E1 genes serve as a packaging cell line, and protective antigenic genes carried are optimized COVID-19 (SARS-CoV-2) S protein genes (Ad5-nCoV). The vaccine has good immunogenicity in both mouse and guinea pig models and can induce the body to produce a strong cellular and humoral immune responses in a short time. Research on the protective effect of hACE2 transgenic mice shows that 14 days after a single Ad5-nCoV immunization, the viral load in lung tissues can be significantly reduced. It shows that the vaccine has a good immune protection effect against COVID-19.
Provided are an mRNA sequence comprising a coding region for encoding at least one antigenic peptide or protein of 2019-nCoV coronavirus or a fragment, variant or derivative thereof, and a composition thereof. Further provided is an application of the described mRNA or composition in the preparation of a drug, in particular a vaccine, for preventing and/or treating 2019-nCoV coronavirus infection.
Provided in the present invention are a carrier protein with a site-directed mutation and the use thereof in the preparation of a vaccine. The amino acid at at least one site on the carrier protein is mutated to an unnatural amino acid containing an azido or alkynyl end group. The carrier protein with site-directed mutation of the present invention can avoid excessive cross-linking with a polysaccharide antigen and can be used to prepare a polysaccharide protein conjugate vaccine.
C07K 14/34 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Corynebacterium (G)
C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
C07K 14/285 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pasteurellaceae (F), p. ex. Haemophilus influenza
C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Medicines for human purposes to treat infectious diseases, namely, covid-19, coronavirus diseases and respiratory diseases and disorders, meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus and shingles; pharmaceutical preparations for treatment or prevention of infectious diseases, namely, covid-19, coronavirus diseases, respiratory diseases and disorders, meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus and shingles; human vaccines; biological preparations for medical use namely, preparations for treating infectious diseases, namely, covid-19, coronavirus diseases, respiratory diseases and disorders, meningitis, pneumonia, tuberculosis, Ebola virus disease, pertussis, diphtheria, tetanus and shingles.
Provided are a glycoconjugate, a specific preparation method for preparing the glycoconjugate by oxidizing a primary hydroxyl group of a bacterial capsular polysaccharide into an aldehyde group and reacting same with a primary amino group of a carrier protein lysine, and an immunogenic composition comprising the glycoconjugate. Also provided is the use of the glycoconjugate and the immunogenic composition in the preparation of drugs or vaccines for preventing and/or treating Streptococcus pneumoniae infections and diseases related with Streptococcus pneumoniae in an individual.
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p. ex. par les adjuvants chimiques
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
Provided are a cell strain HEK293.CS for reducing the production of a replication competent adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace said gene fragment with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of a recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.
Disclosed is a SamRNA vaccine, the vaccine comprising a recombinant viral vector which comprises: i) a viral gene replication complex, the viral gene replication complex comprising nucleotide sequences encoding viral gene replication-related proteins, nsP1, nsP2, nsP3, and nsP4; and ii) a nucleotide sequence encoding at least one antigen.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Vaccines; drugs for medical purposes; diagnostic
preparations for medical purposes; cultures of
microorganisms for medical or veterinary use; dietetic
substances adapted for medical use; depuratives; veterinary
preparations; preparations for destroying noxious animals;
dressings, medical; teeth filling material.
66.
CELL STRAIN FOR REDUCING PRODUCTION OF REPRODUCIBLE ADENOVIRUS, AND CONSTRUCTION METHOD AND USE
Provided are a cell strain HEK293.CS for reducing the production of a reproducible adenovirus, and a construction method and the use thereof. HEK293.CS is a safe adenovirus-producing cell line constructed by knocking out a gene fragment homologous to the Ad5 adenovirus E1 gene in HEK293 and providing a template plasmid to replace same with a non-homologous sequence that stabilizes the expression of the E1 gene. Compared with the unmodified HEK293 cell strain, HEK293.CS shows no decrease in growth ability and virus production ability, but does not produce a detectable RCA. HEK293.CS can be used for the mass culture of the recombinant human type 5 adenovirus, and reducing the probability of RCA production in the manufacture process of drugs such as vaccines and antibodies.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
vaccines; drugs for medical purposes, namely, pharmaceuticals for meningococcal vaccine; diagnostic preparations for medical purposes; cultures of microorganisms for medical or veterinary use; dietetic foods and beverages adapted for medical use; depuratives for the body; preparations for destroying noxious animals; dressings, medical; teeth filling material
68.
Immunogenic composition for preventing pneumococcal diseases and preparation method thereof
Streptococcus pneumonia, covering more than 95% of the strains in clinic. The immunogenic composition has a wide application in the prevention of pneumonia, and is suitable for large-scale production in industry for its simple preparation method, low production cost, and short production cycle.
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
70.
FREEZE-DRYING ADDITIVE FOR ADENOVIRUS AND FREEZE-DRIED PREPARATION OF ADENOVIRUS
A freeze-drying additive for an adenovirus and a freeze-dried preparation of an adenovirus. The freeze-drying additive for an adenovirus is composed of mannitol, sucrose, glycerol, magnesium chloride, a phosphate buffer, and Tween 80. The freeze-dried preparation of the adenovirus is composed of the adenovirus and the freeze-drying additive for the adenovirus, and the adenovirus is a recombinant adenovirus-Ebola virus vaccine.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A method for enhancing immunogenicity of an epitope peptide of an HPV antigen, the method including: assembling a gene of an HPV antigen into a gene of HBc, exogenously expressing a resulting assembled gene to acquire a fusion protein, allowing the fusion protein to automatically assemble to form a virus-like particle including the HPV antigen on a surface of the virus-like particle, to obtain HBc-HPV virus-like particle. A virus-like particle capable of expressing the antigen peptide of HPV acquired by the method. The virus-like particle includes a HBc-L2 fusion protein. A genome for encoding the HBc-L2 fusion protein is represented by SEQ ID NO. 3. A method for preparing an HPV vaccine includes using the virus-like particle.
C12N 15/66 - Méthodes générales pour insérer un gène dans un vecteur pour former un vecteur recombinant, utilisant le clivage et la ligatureUtilisation de linkers non fonctionnels ou d'adaptateurs, p. ex. linkers contenant la séquence pour une endonucléase de restriction
Provided are a fusion protein and a construction method thereof. The fusion protein consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.
Provided are a fusion protein and a construction method thereof. The fusion protein consists of: a Haemophilus influenzae protein D and a Hin47 (Htra) protein. The fusion protein can serve as a protein vehicle for a Haemophilus influenzae polysaccharide-protein conjugate vaccine, thereby increasing immunogenicity of a polysaccharide antigen.
Provided in the present invention are a carrier protein with a site-directed mutation and the use thereof in the preparation of a vaccine. The amino acid at at least one site on the carrier protein is mutated to an unnatural amino acid containing an azido or alkynyl end group. The carrier protein with site-directed mutation of the present invention can avoid excessive cross-linking with a polysaccharide antigen and can be used to prepare a polysaccharide protein conjugate vaccine.
C07K 1/10 - Procédés généraux de préparation de peptides utilisant des agents de couplage
C07K 14/21 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pseudomonadaceae (F)
C07K 14/22 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Neisseriaceae (F), p. ex. Acinetobacter
C07K 14/285 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Pasteurellaceae (F), p. ex. Haemophilus influenza
C07K 14/34 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Corynebacterium (G)
The present disclosure relates to a nebulizing-while-inhaling nebulization administration device. The nebulization administration device includes a quantitative administration control assembly, a drug storage assembly, a nebulization assembly, and a power supply assembly. The drug storage assembly is arranged in the upper housing (9) and is configured for providing a drug liquid for the nebulization assembly. The nebulization assembly is arranged between the upper housing (9) and the lower housing (2) and is configured for nebulizing the drug liquid provided by the drug storage assembly. The administration control assembly is configured for controlling operation of the nebulization assembly. The power supply assembly is configured for supplying power to the administration control assembly and the nebulization assembly. A nebulization outlet is arranged on the lower housing (2) and is configured for discharging the nebulized drug liquid. The nebulization administration device can store and nebulize a liquid pharmaceutical formulation and allows the nebulized liquid pharmaceutical formulation to be inhaled by a patient in real time, thereby achieving such an effect as treatment or immunization.
The present disclosure provides a respiratory syncytial virus-based adenovirus vector vaccine, a method for preparingsame, and use thereof. Specifically, an adenovirus vector suitable for a transmucosal formulation against RSV is selected from a variety of adenovirus vectors. The vaccine is administered by inhalation, which can simulate the virus infection process, stimulate the immune response, and avoid local adverse effects such as injection site pain and the like due to intramuscular injection. By means of inhalation, the atomized vaccine can finally reach the lung through the respiratory tract, thus inducing the respiratory tract mucosal immunity while stimulating the humoral immunity and cellular immunity. The stimulation of the pulmonary mucosal immunity is the most effective method for preventing RSV infection and spread. The vaccine stimulates the lung mucosal immunity and exhibits a well induced humoral immunity level. The present disclosure screens the dose for inhalation and the selected dose is lower compared with the that of the intramuscular injection, thus possessing better safety.
